Search

Boehringer Ingelheim receives Health Canada approval for SENVELGO™, the once-daily liquid oral solution for newly diagnosed diabetes in cats

Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth

• Medicines reached a record 30 million people, driven by JARDIANCE® and OFEV® • R&D investments of 5 billion EUR, or 21 percent of net sales • Net sales rise 10.5 percent (currency adjusted), up strongly to 24.1 billion EUR

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Collaboration key to meeting consumers’ expectations for better animal welfare

Dr. André Desrochers named as the 2019 Metacam® 20* Bovine Welfare Award winner

University of Saskatchewan’s Dr. Diego Moya named 2024 Metacam® Bovine Welfare Award winner

Award recognizes outstanding contributions to advancing animal welfare in Canada

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers